Harman, Samsung Electronics' subsidiary, has unveiled its generative artificial intelligence solution, HealthGPT, tailored for healthcare enterprises. HealthGPT stands as a testament to the company's commitment to advancing patient care by offering real-time clinical insights to professionals and researchers.

Designed on responsible AI foundations, HealthGPT underscores accuracy and has been rigorously verified by healthcare experts. It features an innovative end-to-end framework for language model fine-tuning and data generation, which bolsters its efficiency and performance.

With an eye on cost efficiency and performance, Harman's solution leverages quantization for size reduction, decreasing operational expenses. HealthGPT is poised to revolutionize drug discovery by analyzing clinical trial data, a significant stride paralleling broader industry trends in generative AI estimated to hit a $22 billion market value by 2032.

"HARMAN HealthGPT exemplifies our capabilities in leveraging AI to address industry-specific challenges and deliver customer value,” said Nick Parrotta, Harman's President of Digital Transformation Solutions.